Project Grant K23HL177311
Award Date
7/20/25
Completion Date
6/30/30
Dollars Obligated
$173K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $298,368 to Link Medical LLC to develop a novel device for treating mitral valve regurgitation. The funded project aims to optimize the device design and procedure through bench testing, followed by in vivo feasibility studies. The goal is to create a simpler, more robust, and more effective solution than existing technologies for...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Peca Labs Inc. on August 1, 2025. The grant funds the development and feasibility testing of a novel, fully-polymeric, biomimetic prosthetic mitral valve constructed from clinically-proven materials. The goal is to improve durability, performance, and overall outcomes compared to current biologic and mechanical valve options. Specific aims include...
This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $321,848 to The Trustees of the University of Pennsylvania to conduct research on the role of hemodynamic forces and transcription factors KLF2 and KLF4 in regulating myxomatous valve disease pathogenesis. The research aims to characterize the impact of hemodynamic forces on valve homeostasis, identify specific targets of valve...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
This federal Project Grant award of $1,386,399.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Yale University is for a research project titled "Unraveling Molecular Complexity of Mitral Valve Disease Using Single Cell and Spatial Multi-Omics Analysis". The project aims to construct a single-cell and spatial molecular atlas using mitral valve leaflet samples from both mitral valve prolapse (MVP) patients and healthy individuals....
The National Heart Lung and Blood Institute (NHLBI) awarded a $810,650 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center. The funding will support the development and validation of an artificial intelligence (AI)-enabled algorithm to characterize fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and create an AI-powered risk score to predict...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $2,940,607 to IHC Health Services Inc. (Intermountain Healthcare) to enhance clinical identification of individuals at risk of moderate to severe mitral valve prolapse (MVP) and associated adverse health outcomes. The project aims to: 1) describe the history of MVP, related cardiac morbidities, and contributing conditions using Intermountain...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...